Home / Letter From The Editor (page 115)

Letter From The Editor

Letter from the Editor #486


This week Par Pharmaceutical announced that they had been granted approval to market generic Starlix (Nateglinide). See this week’s New Product. Does the approval of this generic effectively mean we have a new treatment for Diabetes available? I think it does. When Starlix and Prandin first came out, the state …

Read More »

Letter from the Editor #484

Another reason to monitor glucose: Better restaurant service Over the past few weeks I have started increasing my race walking mileage to prepare for a half marathon in November. Although I don’t have diabetes this increase in physical activities seems to run my glucose low in the morning. While driving …

Read More »

Letter from the Editor #481

Steve and I spent a busy 4 days at the AADE, learning the value of education and tighter glucose control for the patients. We would like to thank the nearly 1000 AADE members that stopped by our booth and tried the slow carb muffins. While I was touring the exhibit hall …

Read More »

Letter from the Editor #480

This is an exciting week for many of our readers. As you receive this newsletter over 3,000 of the most recognized experts in Diabetes Care, CDE’s, will be gathering in Atlanta for the American Association of Diabetes Educator’s 36th Annual Meeting. This year there is a lot to talk about. …

Read More »

Letter From The Editor. July 15, 2009 Issue #477

The controversy about Lantus and cancer continues to heat up. Leading experts are coming forward to share their opinions on the meta-analysis. It is too bad that the lay press will never get these expert opinions to our patients. Last week Diabetes Technology & Therapeutics published an outstanding editorial by three …

Read More »